Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 2/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL3650815 | 1.00 | — | — | |
| Sulfuric Acid SCHEMBL16448274 | 1.00 | CA5A (0.55) | CA5ACA5BTSHRCA1ALDH1A1 | |
| Sulfuric Acid SCHEMBL28642679 | 1.00 | CA5A (0.55) | CA5ACA5BTSHRCA1ALDH1A1 | |
| Sulfuric Acid SCHEMBL2840688 | 0.95 | — | — | |
| Sulfuric Acid SCHEMBL30712828 | 0.85 | — | — | |
| Sulfuric Acid SCHEMBL9546784 | 0.84 | CA5A (0.46) | CA5ACA5BTSHRCA1CA9 | |
| Sulfuric Acid SCHEMBL31464825 | 0.80 | — | — | |
| Sulfuric Acid SCHEMBL10744664 | 0.80 | CA5A (0.86) | CA5ACA5BTSHRCA1ALDH1A1 | |
| Sulfuric Acid SCHEMBL11443708 | 0.80 | CA5A (0.86) | CA5ACA5BTSHRCA1ALDH1A1 | |
| Sulfuric Acid SCHEMBL11574785 | 0.80 | CA5A (0.86) | CA5ACA5BTSHRCA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2842957-B1 | METHOD FOR EXTRACTING AND SEPARATING GINKGOLIDES | CHENGDU BAIYU PHARMACEUTICAL CO LTD (CN) | 2017-03-15 | — | — | EP | disclosed |
| US-9084755-B2 | Method for extracting and separating ginkgolides | CHENGDU BAIYU TECHNOLOGY PHARMACY CO., LTD. (CN) | 2015-07-21 | — | — | US | disclosed |
| EP-2842957-A1 | METHOD FOR EXTRACTING AND SEPARATING GINKGOLIDES | Chengdu Baiyu Technology Pharmacy Co., Ltd. (CN) | 2015-03-04 | — | — | EP | disclosed |
| US-20150044311-A1 | METHOD FOR EXTRACTING AND SEPARATING GINKGOLIDES | CHENGDU BAIYU PHARMACEUTICAL CO., LTD. (CN) | 2015-02-12 | — | — | US | disclosed |
| US-8227492-B2 | Sulfoxamine derivatives as factor Xa inhibitors | CADILA HEALTHCARE LIMITED (IN) | 2012-07-24 | — | — | US | disclosed |
| US-20110065717-A1 | SULFOXIMINE DERIVATIVES AS FACTOR XA INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2011-03-17 | — | — | US | disclosed |
| EP-2188257-A2 | SULFOXIMINE DERIVATIVES AS FACTOR XA INHIBITORS | Cadila Healthcare Limited (IN) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009053999-A2 | SULFOXIMINE DERIVATIVES AS FACTOR XA INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065717-A1 | SULFOXIMINE DERIVATIVES AS FACTOR XA INHIBITORS | TFPI, F12, F2 | CA5A 2762/4885CA5B 3204/4885TSHR 1401/4885 |
| US-20150044311-A1 | METHOD FOR EXTRACTING AND SEPARATING GINKGOLIDES | COG8, CYP8B1, GTPBP10 | CA5A 1340/4885CA5B 808/4885TSHR 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.